Sarepta Therapeutics
#1480
Rank
$11.64B
Marketcap
United States
Country
Mr. Douglas S. Ingram Esq. (Pres, CEO & Director)
Mr. Ian Michael Estepan (Exec. VP & CFO)
Mr. William F. Ciambrone (Exec. VP of Technical Operations)
Summary
History
Sarepta started in Corvallis, Oregon on January 1, 1980 and was originally named Antivirals Inc. After occupying several research laboratory spaces in Corvallis, the company opened a production laboratory in Corvallis in February 2002 and was renamed AVI BioPharma Inc. The company made headlines in 2003 when it announced work on treatments for severe acute respiratory syndrome and the West Nile virus. In July 2009, the company announced they would move their headquarters from Portland, Oregon, north to Bothell, Washington, near Seattle. At that time, the company led by president and CEO Leslie Hudson had 83 employees and quarterly revenues of $3.2 million. AVI had yet to turn a profit and had not yet developed any commercial products as of July 2009. The company lost $19.7 million in the second quarter of 2009, and then won an $11.5 million contract with the U.S. Department of Defense's Defense Threat Reduction Agency in October 2009. By this time, the company had completed its headquarters move to Bothell.In 2012, the company moved a second time, to Cambridge, Massachusetts. At the time, CEO Chris Garabedian indicated the move was motivated by the need to recruit expertise in rare diseases. The Corvallis laboratory facility was closed in 2016.
In February 2019, Sarepta acquired five gene therapy candidates for $165 million after one of them, MYO-101, produced results with a new gene therapy candidate for patients with Limb-Girdle muscular dystrophy; two months after receiving a single treatment, muscles from all three patients were producing the protein they couldn't make on their own.As of 2022, there are three FDA-approved Duchenne muscular dystrophy drugs in Sarepta Therapeutics' portfolio.
Mission
Vision
Key Team
Dr. Louise R. Rodino-Klapac Ph.D. (Exec. VP, Chief Scientific Officer and Head of R&D)
Mr. Ryan E. Brown (Sr. VP, Gen. Counsel & Corp. Sec.)
Bilal Arif (Sr. VP of Strategy and Operations)
Mary Jenkins (Sr. Mang. of Investor Relations)
Ms. Alison Nasisi (Chief People Officer & VP)
Dr. Diane L. Berry (Sr. VP of Global Health Policy and Gov. & Patient Affairs)
Mr. Dallan Murray (Sr. VP & Chief Customer Officer)
Recognition and Awards
References
https://en.wikipedia.org/wiki/Sarepta_Therapeutics
https://in.investing.com/equities/sarepta
https://finance.yahoo.com/quote/SRPT/profile?p=SRPT
https://www.comparably.com/companies/sarepta-therapeutics/mission
https://www.crunchbase.com/organization/sarepta-therapeutics
https://sec.report/CIK/0000873303
Mr. Douglas S. Ingram Esq. (Pres, CEO & Director)
Mr. Ian Michael Estepan (Exec. VP & CFO)
Mr. William F. Ciambrone (Exec. VP of Technical Operations)